Comparing Revolutions Medical (OTCMKTS:RMCP) & Penumbra (NYSE:PEN)

Revolutions Medical (OTCMKTS:RMCP) and Penumbra (NYSE:PEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares Revolutions Medical and Penumbra”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolutions Medical	N/A	N/A	N/A	N/A	N/A
Penumbra	$1.19 billion	8.28	$90.95 million	$0.34	755.36

Penumbra has higher revenue and earnings than Revolutions Medical.

Profitability

This table compares Revolutions Medical and Penumbra’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolutions Medical	N/A	N/A	N/A
Penumbra	1.17%	9.74%	7.35%

Volatility & Risk

Revolutions Medical has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Revolutions Medical and Penumbra, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolutions Medical	0	0	0	0	0.00
Penumbra	0	3	12	1	2.88

Penumbra has a consensus target price of $292.64, suggesting a potential upside of 13.95%. Given Penumbra’s stronger consensus rating and higher probable upside, analysts plainly believe Penumbra is more favorable than Revolutions Medical.

Insider and Institutional Ownership

88.9% of Penumbra shares are owned by institutional investors. 10.5% of Revolutions Medical shares are owned by insiders. Comparatively, 5.0% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Penumbra beats Revolutions Medical on 10 of the 11 factors compared between the two stocks.

About Revolutions Medical

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.